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Abstract
Background: To develop and compare delta-radiomics signatures from 2- (2D) and 3-dimensional (3D) features that
predict treatment outcomes following preoperative chemoradiotherapy (CCRT) and surgery for locally advanced
rectal cancer.
Methods: In total, 101 patients (training cohort, n = 67; validation cohort, n = 34) with locally advanced rectal
adenocarcinoma between 2008 and 2015 were included. We extracted 55 features from T2-weighted magnetic
resonance imaging (MRI) scans. Delta-radiomics feature was defined as the difference in radiomics feature before
and after CCRT. Signatures were developed to predict local recurrence (LR), distant metastasis (DM), and disease-
free survival (DFS) from 2D and 3D features. The least absolute shrinkage and selection operator regression was
used to select features and build signatures. The delta-radiomics signatures and clinical factors were integrated
into Cox regression analysis to determine if the signatures were independent prognostic factors.
Results: The radiomics signatures for LR, DM, and DFS were developed and validated using both 2D and 3D features.
Outcomes were significantly different in the low- and high-risk patients dichotomized by optimal cutoff in both the
training and validation cohorts. In multivariate analysis, the signatures were independent prognostic factors even when
considering the clinical parameters. There were no significant differences in C-index from 2D vs. 3D signatures.
Conclusions: This is the first study to develop delta-radiomics signatures for rectal cancer. The signatures successfully
predicted the outcomes and were independent prognostic factors. External validation is warranted to ensure
their performance.
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Background
After the landmark randomized trial [1], preoperative
chemoradiotherapy (CCRT) followed by total mesorectal
excision (TME) has been a standard treatment strategy for
locoregionally advanced rectal cancer. However, efforts
have been continuously made to promote risk-adaptive
therapy. One such approach is local excision [2, 3] or even
observation [4, 5], rather than TME, in good responders
following CCRT to reduce the risk of impaired quality of
life. Alternatively, adding chemotherapeutic agents or
intensifying radiation doses may be attempted in patients
with poor response or prognosis [6–8]. These strategies
can be implemented with the help of treatment outcome
predictors; however, there are still no tools explicitly
available for this purpose.
Radiomics provide image features associated with cli-
nical characteristics or outcomes that are extracted from
medical images. Numerous studies have been conducted
on various cancer types, including lung cancer [9], glioma
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[10], and head and neck cancer [11] as well as proposed
radiomics-based predictors of good performance. Radio-
mics models for rectal cancer have recently been developed
using computed tomography (CT), magnetic resonance
imaging (MRI), and positron emission tomography (PET)
[12–18]. Some researchers have built radiomics models to
predict pathologic response to CCRT [12, 13, 17, 18].
Meng et al. [14] reported a radiomics signature to pre-
dict disease-free survival (DFS) using pretreatment MRI
in which the models could predict the treatment re-
sponse or prognosis with acceptable predictability.
Nonetheless, clinical response to treatment is another
important indicator and may improve the performance
of the models. Although treatment response is an im-
portant prognostic factor, it cannot describe the entire
details of response. In this context, some researchers
have examined delta-radiomic features, which are the
differences in radiomic features before and after treat-
ment. Delta-radiomics deals with serial changes in
images, which is one of the major parts of radiologic
studies. Delta-radiomics features have been reported to be
associated with treatment response or outcome [19, 20];
however, reports on delta-radiomics in rectal cancer
are less [21].
In this paper, we have focused on applying delta-
radiomics features extracted from T2-weighted MRI
to build prediction signatures for treatment outcomes




This retrospective study was approved by the institutional
review board of our hospital; the requirement of informed
consent was waived. The protocol was compliant with the
Health Insurance Portability and Accountability Act. We
retrospectively enrolled patients with locally advanced
(cT3–4 and/or cN1–2) biopsy-proven rectal adenocarcin-
oma treated at our institution with preoperative CCRT
and TME between 2008 and 2015. Patients with the
following were excluded: distant metastasis (DM) at the
time of diagnosis, MRI with poor quality (e.g., artifact), or
slice spacing of MRI not 4mm (to minimize the influence
of different voxel sizes). Included patients were randomly
allocated to the training or validation cohort in a 2:1 ratio.
Treatment outcome
We examined local recurrence (LR), DM, and DFS. LR
and DM were defined as recurrences inside and outside
the true pelvis, respectively. DFS was calculated as time
from beginning of preoperative CCRT to death from any
cause or recurrence.
Image protocol
An MRI scan was obtained for each patient before pre-
operative CCRT (MRI-before) and before TME after
completion of CCRT (MRI-after). MRI-after was
acquired at 72 days (median; interquartile range, 70–78)
after the start of CCRT. MRI was performed using 1 .5T
Gyroscan Intera, 3 T Achieva, or 3 T Ingenia MR scan-
ners (Philips Medical Systems, Best, Netherlands). The
protocol included T2-weighted sequences using the fol-
lowing parameters: repetition time, 2424–8296ms; echo
time, 92–120 ms; flip angle, 90°; slice thickness, 3 mm;
slice spacing, 4 mm; matrix, 512 × 512–576 × 576.
Segmentation
Each region of interest (ROI) was segmented on all
T2-weighted axial with reference to diffusion-weighted
imaging (DWI) sequences. On MRI-before, the ROI was
delineated on the tumor with an area of low to inter-
mediate signal intensity on T2-weighted images, exclud-
ing the intestinal lumen. The ROI on MRI-after was
defined as residual tumor and/or rectal tissues with
abnormal signal intensity on T2-weighted images where
tumor preexisted [13]. Bladder urine of approximately
1-cm3 sphere volume was drawn to obtain average
pixel value of bladder urine which was used for
normalization. Segmentation of all patients was per-
formed manually using the Eclipse system (Varian
Medical Systems, Palo Alto, CA, USA) by a radiation
oncologist with 12-year experience in gastro-intestinal
tumor. Representative examples of tumor segmen-
tations are demonstrated on Fig. 1.
Image preprocessing and feature extraction
Image preprocessing and feature extraction were per-
formed using in-house MATLAB R2017b software (Math-
Works, Natick, MA, USA). For preprocessing, Collewet
normalization algorithm [22] was used to reduce the
differences between image acquisition protocols. All pixel
values were normalized to average intensity of bladder
urine [23] to improve image reproducibility. Pixel
values were quantized into 64 levels with bladder urine
signal intensity corresponding to the highest level. The
3-dimensional ROIs were isotropically resampled to
1 × 1 × 1-mm3 voxels. For 2-dimensional analysis, the
ROI on the axial slice with the largest area was selected
and resampled to 1 × 1-mm2 pixels.
Within each ROI, (a) volume (or area in 2-dimensional
analysis), (b) 8 first-order features, (c) 15 texture features
from gray level co-occurrence matrix, (d) 13 texture
features from gray level run length matrix, (e) 13 texture
features from gray level size zone matrix, and (f) 5 texture
features from neighbor gray tone difference matrix were
extracted. The details and list of the extracted features are
described in Additional file 1: Appendix A and Table B1,
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respectively. The delta-radiomics feature was defined as
the difference between features on MRI-before and
MRI-after and calculated as follows:
Delta−radiomic Feature ¼ FeatureMRI−after−FeatureMRI−before
Feature selection and statistical analysis
Robustness of each feature was evaluated by generating
translated ROIs and calculating their features. The
method was modified from the stability test introduced
by Bologna et al. [24] Eight translated ROIs representing
inter-observer variability were generated by translating
ROI by ±1mm in lateral and/or ± 1mm in vertical direc-
tions; 0 mm in both directions yields the original ROI
and is thus excluded from the robustness test. After
extracting the features from the original ROI and 8
translated ROIs, intraclass correlation coefficient (ICC)
values were calculated for each feature. Features with
ICC > 0.9 in both 3D and 2D extraction in MRI-before
and MRI-after were considered robust and selected. This
process substituted the comparison of features derived
from multiple observers.
The least absolute shrinkage and selection operator
(LASSO) method was used to select core features and to
develop score-based signatures in the training cohort.
The final value of λ, a tuning parameter, was determined
by 10-fold cross-validation, which gave minimum
cross-validation error. A radiomics score (Rad score)
was generated by linearly combining the selected core
features and their respective coefficients. Consequently,
the optimal cutoff of Rad score, making the greatest
difference in outcome between the two groups divided
by the cutoff, was determined.
The differences in clinical and treatment parameters
between the training and validation cohort were eva-
luated using the Student’s t-test or chi-squared test, as
appropriate. Survival outcomes were compared between
these cohorts using the log-rank test. Univariate and multi-
variate analyses of clinical factors and radiomics scores
were performed using the Cox proportional hazards model.
Performance of the models were evaluated with area under
the ROC curve (AUC) and Hosmer-Lemeshow goodness-
of-fit test, and the relationship between radiomics scores
was quantified using Pearson correlation coefficient and
variance inflation factor (VIF). Variables with a significant
association were integrated into multivariate analysis; the
association was considered significant when p < 0.05. R
software version 3.5.0 was used to perform all statistical
analyses (http://www.r-project.org).
Results
Patients and treatment characteristics
A total of 101 patients were included in the analysis,
with 67 in the training and 34 in the validation cohort.
The median follow-up duration was 49.7 months (range,
9.3–99.4). Clinical characteristics of the two cohorts are
summarized in Table 1. There was no significant differ-
ence between the two cohorts.
All patients received radiotherapy doses of 50.4 Gy in 28
fractions to the primary tumor and regional lymphatics
with the 2D (n = 18) or 3D (n = 83) technique. Additio-
nally, 5-fluorouracil (n = 19) or capecitabine (n = 82) was
administered concurrently with radiotherapy. TME-based
surgery was performed at a median 48 days (range, 28–90)
after the end of CCRT. Adjuvant chemotherapy was
administered in 91 patients (90.1%); fluorouracil and
leucovorin in 20, capecitabine in 36, uracil and tegafur in
7, and FOLFOX in 28 patients, respectively.
Development and validation of Delta-Radiomics signature
The delta-radiomics signature was developed using the
remaining 22 features after the robustness test. The 22
Fig. 1 Examples of tumor segmentation on MRI acquired (a) before and (b) after preoperative CCRT
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robust features with ICC > 0.9 are listed in Additional file 1:
Appendix Table B2. LASSO Cox regression analysis was
conducted in the training cohort to select radiomics fea-
tures with non-zero coefficients. Rad scores predicting
LR, DM, and DFS are as follows:
LR 3D Radscore ¼ −5:9627417 10−5 x Volume
þ 4:0761146
 IntEnergy−135:5705805
 GLCMEnergy þ 286:7201809
 GLCMSumAverage
þ 2:7222298 x 10−3
 GLCMAutocorrelation þ 0:1212618
 GLSZMLZLGLE−263:8275908
NGTDMCoarseness
LR 2D Radscore ¼ −3:9078995 10−4  Volume
þ 2:4888091
 IntEnergy−22:2879655








þ 1:3710706 x 10−4




DM 2D Radscore ¼ 0:4580866
 IntEnergy−45:2277485
NGTDMCoarseness




þ 1:1112033 x 10−4
 GLRLMLRHGLE−101:5991090
NGTDMCoarseness
Table 1 Patient characteristics of training and validation cohort
Training cohort (N = 67) Validation cohort (N = 34) P-value
Age 59.5 ± 11.6 62.5 ± 11.4 0.22a
Sex Male 54 (80.6%) 22 (64.7%) 0.13b
Female 13 (19.4%) 12 (35.3%)
Clinical T stage cT1–3 59 (88.1%) 30 (88.2%) 1.00b
cT4 8 (11.9%) 4 (11.8%)
Clinical N stage cN0 9 (13.4%) 5 (14.7%) 1.00b
cN1–2 58 (86.6%) 29 (85.3%)
Dworak TRG 1 15 (22.4%) 4 (11.8%) 0.64b
2 27 (40.3%) 16 (47.1%)
3 14 (20.9%) 8 (23.5%)
4 11 (16.4%) 6 (17.6%)
Pathologic T stage ypT0–2 37 (55.2%) 16 (47.1%) 0.57b
ypT3–4 30 (44.8%) 18 (52.9%)
Pathologic N stage ypN0 46 (68.7%) 22 (64.7%) 0.86b
ypN1–2 21 (31.3%) 12 (35.3%)
Initial CEA ≤5 ng/mL 42 (62.7%) 24 (70.6%) 0.57b
> 5 ng/mL 25 (37.3%) 10 (29.4%)
Local recurrence Yes 8 (11.9%) 2 (5.9%) 0.54b
No 59 (88.1%) 32 (94.1%)
Distant metastasis Yes 16 (23.9%) 6 (17.6%) 0.64b
No 51 (76.1%) 28 (82.4%)
aStudent’s t-test
bChi-squared test
Abbreviations: TRG tumor regression grade, CEA carcinoembryonic antigen
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DFS 2D Radscore ¼ 0:3188674
 IntEnergy−44:9766973
NGTDMCoarseness
Optimal cutoff values of Rad scores were determined
and used to divide the cohort into high- and low-risk
groups, and a higher score was correlated to a higher
risk. In the training cohort, all Rad scores were signifi-
cantly associated with respective outcomes (all p < 0.05,
log-rank test). The prognostic performance of all Rad
scores was validated in a randomly selected cohort. All
Rad scores significantly stratified the risk in the 2
groups (all p < 0.05, log-rank test). The Kaplan-Meier
survival curves for LR, DM, and DFS according to 3D
and 2D Radscores are demonstrated on Fig. 2 and
Fig.3, respectively. The AUC and Hosmer-Lemeshow
Chi-square values suggest that the predictability of the sig-
natures is acceptable and are detailed on Additional file 1:
Appendix Table C.
Integration with clinical features
Univariate analysis followed by multivariate analysis was
performed to verify radiomics scores as independent
prognostic factors for the respective endpoints in the
combined cohort. Detailed results of the analyses are
presented in Additional file 1: Appendix Table D1–3. All
radiomics scores, regardless of 2D or 3D signature, were
significantly associated with the corresponding outcomes
on multivariate analysis.
Comparisons of 3D and 2D signatures
Correlations between 3D and 2D Rad scores were inves-
tigated in the 101 patients. Pearson correlation coeffi-
cients of 3D and 2D Rad scores for LR, DM, and DFS
were 0.840 (95% CI = 0.771–0.889, p < 0.0001, VIF =
3.39), 0.641 (95% CI = 0.510–0.743, p < 0.0001, VIF =
1.70), and 0.665 (95% CI = 0.540–0.761, p < 0.0001, VIF =
1.79), respectively. The scatterplot of Rad scores and their
correlations are shown in Fig. 4.
The value of C-index was calculated and compared for
each Rad score. In terms of all outcomes, the C-indices
between the 2D and 3D Rad scores, both as continuous
and binary variables divided by cutoff, were not signifi-
cant (Table 2).
Discussion
In the present study, we developed and validated the
prognostic role of delta-radiomics signatures in locally
advanced rectal cancer treated with preoperative
CCRT and surgery. Furthermore, we compared the
performance of 2D and 3D radiomics features. To our
knowledge, this is the first publication to incorporate
delta-radiomics features to predict recurrences in
rectal cancer.
A good response to preoperative CCRT is consistently
associated with improved treatment outcomes of rectal
cancer [25, 26]. Although pretreatment radiomics fea-
tures predict pathologic tumor response, they do not
contain all of the information regarding response.
Images following preoperative CCRT can reveal indi-
cators of tumor response. Tumor regression grade
according to post-treatment T2-weighted MRI is corre-
lated with pathologic tumor regression grade [27, 28].
Thus, we hypothesized that delta-radiomics features on
T2-weighted MRI have prognostic power. A recent study
showed correlation between delta-radiomics features and
clinical response in rectal cancer [21]. Analyzing 16
patients, the study provided an evidence of clinical sig-
nificance of delta-radiomics features. Since there are no
studies with large patients concerning delta-radiomics,
however, we strictly limited the number of features
included in the investigation. We only included the
features that are widely used in radiomics studies, and
the image preprocessing step was onefold. Furthermore,
we included the features with ICC > 0.9 in all 3D and
2D analyses, leaving 22 features for LASSO regression.
The developed Rad scores were successfully validated
in a randomly selected cohort. Some radiomics features
may be closely related to clinical factors, thus the signa-
tures should be independent prognostic factors in multi-
variate analysis to be valuable. Rad scores along with
clinical factors consistently reported to be prognostic
were independently associated with treatment outcomes.
Remarkably, post-treatment pathologic characteristics
such as pathologic stage and tumor regression grade are
incorporated in the analysis. The results suggest that
delta-radiomics features may contain more information
than microscopic findings, e.g., tumor genotype or
microenvironment.
The developed signatures are believed to be useful in
daily practice. There is no consensus regarding the use
of adjuvant chemotherapy after preoperative CCRT and
surgery. Subgroups that may benefit from adjuvant
chemotherapy have been reported [29–31]. It is gener-
ally hypothesized that patients at high risk of recurrence,
usually those with distant metastasis, benefit from adju-
vant chemotherapy. Most of the patients (90.1%) in our
study received adjuvant chemotherapy, suggesting that,
for patients with low Rad scores, adjuvant chemotherapy
can be omitted.
We compared 2D and 3D delta-radiomics signatures
in predicting outcomes. One major advantage of the
radiomics approach is that it can represent properties of
the whole tumor. However, in the case of 2D features,
only part of the tumor is segmented. Therefore, there are
concerns regarding the power of 2D radiomics features.
The main advantage of 2D radiomics features is the con-
venience in investigation and application; investigators or
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Fig. 2 Kaplan–Meier curves of (a) local recurrence, (b) distant metastasis, and (c) disease-free survival according to optimal cutoffs of 3D Rad
scores. P-values from log-rank test are shown
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Fig. 3 Kaplan–Meier curves of (a) local recurrence, (b) distant metastasis, and (c) disease-free survival according to optimal cutoffs of 2D Rad
scores. P-values from log-rank test are shown
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users only need to delineate the tumor on 1 representative
slice. In addition, 2D features, particularly slice thickness
and spacing, may be less dependent on the image-acquir-
ing protocol. Several authors have utilized 2D radiomics
features of rectal cancer and reported their predictive
power [32–34]. As rectal cancer usually grows along the
wall and has an irregular shape, the segmented whole
tumor may not represent its actual shape [35]; hence, 2D
radiomics features need to be further studied. Regarding
all outcomes, both 2D and 3D Rad scores were inde-
pendent prognostic factors on multivariate analysis. By
comparing C-index, 2D and 3D Rad scores were not
statistically different in prognostic power, possibly because
of the high correlation between scores. Hence, our data
suggest that 2D delta-radiomics features can be investi-
gated as a good surrogate for 3D features of rectal cancer.
One of the drawbacks of our study is the exclusion of
functional images such as DWI or other modalities such
as CT and PET. Several studies have reported the corre-
lation between DWI parameters and response or out-
comes after CCRT [36–38]. Recent work by Giannini
and colleagues demonstrated the role of PET-derived
radiomics features in predicting treatment response [18].
We believe that the performance of delta-radiomics sig-
nature would improve with the incorporation of other
sequences or modalities. We hope that radiomics fea-
tures from various images can be used in subsequent
delta-radiomics investigations. Another limitation of the
study is the different parameters of the analyzed
T2-weighted images. We normalized the pixel intensity
using Collewet’s method and urine intensity and
resampled the voxels or pixels into isometric cubes or
squares. Nonetheless, the preprocessing steps cannot
fully compensate for the differences. However, we be-
lieve that the radiomics signature should be applicable
to various image protocols for widespread clinical use.
In that context, the wide applicability of our signatures
needs to be tested in MRIs from other institutions.
In conclusion, we developed radiomics scores to pre-
dict treatment outcomes after preoperative CCRT and
surgery. The results support further investigation of
delta-radiomics features in rectal cancer. The 2D and 3D
delta-radiomics features were similarly informative.
External validation of our signatures is necessary to
ensure their performance.
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DM: Distant metastasis; DWI: Diffusion-weighted image; ICC: Intraclass
correlation coefficient; LASSO: Least absolute shrinkage and selection




Fig. 4 The scatterplots between 3D and 2D Rad scores of the entire cohort (n = 101) predicting (a) local recurrence, (b) distant metastasis, and (c)
disease-free survival. Linear fit lines and 95% confidence intervals were drawn, and presented coefficients and p-values were calculated using
Pearson correlation coefficient
Table 2 Comparison of C-indices of 3D and 2D Rad-scores. The




Continuous 0.893 ± 0.035 0.873 ± 0.050 0.24
Binary 0.951 ± 0.026 0.926 ± 0.054 0.29
DM Rad-score
Continuous 0.783 ± 0.039 0.774 ± 0.042 0.38
Binary 0.894 ± 0.048 0.911 ± 0.040 0.64
DFS Rad-score
Continuous 0.788 ± 0.039 0.763 ± 0.041 0.22
Binary 0.897 ± 0.046 0.886 ± 0.048 0.41
Abbreviations: LR local recurrence, DM distant metastasis, DFS
disease-free survival
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